Drug intelligence / Profile preview

VRP-1018

Development stage: Preclinical
Lead developer: Venus Remedies
Modality: Small Molecules

Overview

VRP-1018 is a natural product-derived antioxidant currently in preclinical development by Venus Remedies. It is being investigated for the treatment of oxidative stress-related conditions, which encompass a wide range of chronic and degenerative diseases characterized by an imbalance between reactive oxygen species (ROS) production and the body's antioxidant defenses. As a natural antioxidant, VRP-1018 is intended to neutralize free radicals and mitigate oxidative damage to cellular components such as lipids, proteins, and DNA. The specific chemical composition and molecular targets of VRP-1018 have not been publicly disclosed by the sponsor.

Other names: Natural Anti-oxidant

Beyond the preview

Go deeper on VRP-1018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRP-1018.

Explore the full profile